SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hsieh T,Lee MP,Brown SD. Structure of eukaryotic type I DNA topoisomerase. Adv Pharmacol. 1994; 29A: 191200.
  • 2
    Morham SG,Kluckman KD,Voulomanos N,Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol. 1996; 16: 68046809.
  • 3
    Huang P,Chubb S,Hertel LW,Grindey GB,Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991; 51: 61106117.
  • 4
    Ryan AJ,Squires S,Strutt HL,Johnson RT. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 1991; 19: 32953300.
  • 5
    Pourquier P,Gioffre C,Kohlhagen G, et al. Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res. 2002; 8: 24992504.
  • 6
    Tolis C,Peters GJ,Ferreira CG,Pinedo HM,Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer. 1999; 35: 796807.
  • 7
    Bahadori H,Lima CM,Green MR,Safa AR. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res. 1999; 19: 54235428.
  • 8
    Stewart L,Ireton GC,Champoux JJ. The domain organization of human topoisomerase I. J Biol Chem. 1996; 271: 76027608.
  • 9
    Alsner J,Svejstrup JQ,Kjeldsen E,Sorensen BS,Westergaard O. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function. J Biol Chem. 1992; 267: 1240812411.
  • 10
    Stewart L,Ireton GC,Parker LH,Madden KR,Champoux JJ. Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem. 1996; 271: 75937601.
  • 11
    Christensen MO,Barthelmes HU,Boege F,Mielke C. The N-terminal domain anchors human topoisomerase I at fibrillar centers of nucleoli and nucleolar organizer regions of mitotic chromosomes. J Biol Chem. 2002; 277: 3593235938.
  • 12
    Mo YY,Wang C,Beck WT. A novel nuclear localization signal in human DNA topoisomerase I. J Biol Chem. 2000; 275: 4110741113.
  • 13
    Valkov NI,Gump JL,Engel R,Sullivan DM. Cell density- dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm. Br J Haematol. 2000; 108: 331345.
  • 14
    Daud A,Valkov N,Centeno B, et al. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res. 2005; 11: 30093016.
  • 15
    Alberts SR,Erlichman C,Sloan J, et al. Phase I trial of gemcitabine and CPT-11 given weekly for 4 weeks every 6 weeks. Ann Oncol. 2001; 12: 627631.
  • 16
    Lima CM,Leong SS,Sherman CA, et al. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park). 2002; 16( 5 suppl 5): 1924.
  • 17
    Kakolyris SS,Kouroussis C,Koukourakis M, et al. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res. 2002; 22: 18911896.
  • 18
    Dent S,Messersmith H,Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res. Treat. 2008; 108: 319331.
  • 19
    Grunewald R,Abbruzzese JL,Tarassoff P,Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991; 27: 258262.
  • 20
    Sumiyoshi H,Fujiwara Y,Ohune T,Yamaoka N,Tamura K,Yamakido M. High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B Biomed Appl. 1995; 670: 309316.
  • 21
    Sparreboom A,de Bruijn P,de Jonge MJ, et al. Liquid chromatographic determination of irinotecan and 3 major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl. 1998; 712: 225235.
  • 22
    Mick R,Gupta E,Vokes EE,Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol. 1996; 14: 20122019.
  • 23
    Abbruzzese JL,Grunewald R,Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9: 491498.
  • 24
    Kroep JR,Giaccone G,Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol. 1999; 17: 21902197.
  • 25
    Smorenburg CH,Bontenbal M,Seynaeve C, et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat. 2001; 66: 8387.
  • 26
    Rha SY,Moon YH,Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005; 90: 215221.
  • 27
    Brodowicz T,Kostler WJ,Moslinger R, et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast. 2000; 9: 338342.
  • 28
    Spielmann M,Llombart-Cussac A,Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology. 2001; 60: 303307.
  • 29
    Modi S,Currie VE,Seidman AD, et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005; 6: 5560.
  • 30
    Chan S,Romieu G,Huober T, et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European Phase III study. J Clin Oncol. 2005; 23( 16 suppl): A851.
  • 31
    Albain KS,Nag SM,Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008; 26: 39503957.
  • 32
    Blackstein M,Vogel CL,Ambinder R,Cowan J,Iglesias J,Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002; 62: 28.
  • 33
    Carmichael J,Possinger K,Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995; 13: 27312736.
  • 34
    Abigerges D,Chabot GG,Armand JP,Herait P,Gouyette A,Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995; 13: 210221.
  • 35
    Perez EA,Hillman DW,Mailliard JA, et al. Randomized phase II study of 2 irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004; 22: 28492855.